Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy - a Phase II Study.

Trial Profile

Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy - a Phase II Study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2013

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Lapatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Mar 2012 Planned End Date changed from 1 Dec 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 24 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 10 Mar 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top